Drugs / MAGE-3.A1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01723813 | Apr 2012 → Apr 2015 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
| Phase 1/2 | NCT01191034 | Aug 2010 → Aug 2012 | metastatic melanoma | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-3.A1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01723813 ↗ |
| Modality | Peptide | “The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor.” NCT01191034 ↗ |